Glaukos Technologies Featured in Various Presentations at 2016 American Academy of Ophthalmology Conference
Fresh News,
SAN CLEMENTE, Calif. — (BUSINESS WIRE) — Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
SAN CLEMENTE, Calif. — (BUSINESS WIRE) — Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
] Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on development and commercialization of…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic medical technology company focused on…
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on development and commercialization of…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS ), an ophthalmic medical technology company focused on…
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on development and commercialization of…
SAN CLEMENTE, Calif.--(Business Wire)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
SAN CLEMENTE, Calif.--( BUSINESS WIRE )-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology company focused on…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on…
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on development and commercialization of…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on…
Oct. 6, 2016 11:00 UTC SAN CLEMENTE, Calif.--( BUSINESS WIRE )-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical…
Study in Clinical Ophthalmology Reveals Mean IOP of 15.17 mm Hg and 56% Reduction in Mean Glaucoma Medications 2 Years…
Study in Clinical Ophthalmology Reveals Mean IOP of 15.17 mm Hg and 56% Reduction in Mean Glaucoma Medications 2 Years…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…
SAN CLEMENTE, Calif.--(Business Wire)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of…
SAN CLEMENTE, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…
(NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough…
Sept. 27, 2016 11:00 UTC SAN CLEMENTE, Calif.--( BUSINESS WIRE )-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical…
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
SAN CLEMENTE, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
LAGUNA HILLS, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
Sept. 22, 2016 20:30 UTC LAGUNA HILLS, Calif.--( BUSINESS WIRE )-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical…
Newly Diagnosed Primary Open-Angle Glaucoma Patients Who Received 2 iStents Achieved 43% Reduction in Mean Intraocular Pressure…
] Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization…
Newly Diagnosed Primary Open-Angle Glaucoma Patients Who Received 2 iStents Achieved 43% Reduction in Mean Intraocular Pressure…
Newly Diagnosed Primary Open-Angle Glaucoma Patients Who Received 2 iStents Achieved 43% Reduction in Mean Intraocular Pressure…
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of…
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS ), an ophthalmic medical technology company focused on…
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…
LAGUNA HILLS, Calif.--(Business Wire)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
LAGUNA HILLS, Calif.--( BUSINESS WIRE )--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on…
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Glaukos Corporation ( GKOS ), an ophthalmic medical technology company focused on the…
(NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough…
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of…